Business Context and Reporting Period
IN8bio, Inc. filed a Form 8-K dated November 15, 2021, under Item 5.02 to report the appointment of Dr. Trishna Goswami as Chief Medical Officer, effective November 15, 2021. The company is a Delaware corporation whose common stock trades on Nasdaq under the symbol INAB.
Financial and Liquidity Information
This filing does not provide revenue, profit or loss, cash flow, margin, debt, cash balance, liquidity, or other operating financial metrics. The filing text does not provide a clear value for these items.
Material Changes Versus the Prior Comparable Period
- Dr. Goswami was appointed Chief Medical Officer, representing a change in the company’s executive leadership.
- The filing does not report comparative financial results or other period-over-period operating changes.
Compensation, Outlook, and Unusual Items
- Dr. Goswami will be employed on an at-will basis at an annual base salary of $450,000.
- She is eligible for an annual bonus targeted at 40% of base salary.
- She received a $10,000 signing bonus, subject to repayment if she resigns without Good Reason before the first anniversary of her start date.
- She will receive an option to purchase 250,000 shares of common stock, vesting over four years, with 25% vesting after the first anniversary of the grant date, subject to continued employment.
- If terminated by the company without Cause or by Dr. Goswami for Good Reason, subject to specified conditions including execution of a release and settlement agreement, she may receive 12 months of then-current base salary, the pro rata portion of her target bonus assuming performance goals are completed, and nine months of COBRA premiums.
- Management guidance, clinical or commercial forecasts, and other outlook information are not provided in this filing.
- The full employment agreement is to be filed as an exhibit to the company’s Form 10-K for the year ending December 31, 2021.
Key Investor Verification Items
- Review the full employment agreement when filed for the complete definitions of Cause and Good Reason, severance conditions, and other obligations.
- Assess the potential dilution and accounting expense associated with the 250,000-share stock option.
- Monitor subsequent filings for changes in executive leadership, compensation, or employment status.
- Use the company’s periodic financial statements to verify cash, liquidity, operating expenses, and funding requirements, which are not addressed in this 8-K.